Malignant neoplasm of anus

Oncolytics Biotech Expands GI Tumor Scientific Advisory Board with Eileen O’Reilly, Neil Segal, and Van Morris

3 weeks ago talkbio0Tagged biotech, Colorectal Carcinoma, Gastrointestinal Neoplasms, GI oncology, Malignant neoplasm of anus, Neil Segal, Oncolytics, Pancreatic carcinoma, pelareorep, platform immunotherapy * *, Scientific Advisory Board, Van Morris

Oncolytics Biotech; gastrointestinal tumor; Scientific Advisory Board; Neil Segal; Van Morris; pelareorep; pancreatic cancer; colorectal cancer; anal cancer; GI oncology; platform immunotherapy

Incyte’s Zynyz Secures FDA Approval for Anal Cancer After Previous Rejection

8 months ago talkbio0Tagged Approved, Clinical Trials, Combination Drug Therapy, first-line therapy, Immunotherapy, Incyte, Inhibitor, Malignant neoplasm of anus, PDCD1 gene, POD1UM-303, Retifanlimab, United States Food and Drug Administration, Zynyz

Incyte; Zynyz; retifanlimab; FDA approval; anal cancer; PD-1 inhibitor; first-line therapy; immunotherapy; clinical trial; POD1UM-303; combination chemotherapy

Incyte’s PD-1 Drug Zynyz: A Strategic Pipeline Component Despite Recent Trial Success

1 year ago talkbio0Tagged Approved, Clinical Trials, Incyte, Inhibitor, Malignant neoplasm of anus, PDCD1 gene, United States Food and Drug Administration, Zynyz

Incyte, Zynyz, PD-1 inhibitor, anal cancer, pipeline strategy, clinical trials, FDA approval